Not all that glitters is gold: A guide to critical appraisal of animal drug trials in epilepsy

Abstract

SummaryPreclinical studies have produced numerous drugs with antiseizure properties that currently are the standard of care. One third of the human population with epilepsy still continues to have seizures despite the ongoing discoveries. The recognized clinical gaps of care that need to be addressed are the identification of antiepileptogenic and disease‐modifying treatments, and treatments for refractory seizures or for seizures and epilepsies with limited or unsatisfactory treatments, such as early life epileptic encephalopathies. In this invited review, we provide a historical summary of the international efforts to reevaluate the strategies adopted in preclinical epilepsy therapy discovery studies. We discuss issues that may affect the quality, interpretation, and validation of preclinical studies and their translation to successful therapies for humans affected with epilepsy. These include the selection of animal models and the study design; research practices that affect rigor (such as appropriate use of statistics and reporting of study methods and results, their validation across models, labs, and preclinical‐clinical studies); the need to harmonize research methods and outcome assessment; and the importance of improving translation to clinically appropriate situations. The epilepsy research community is incrementally adopting collaborative research, including consortia or multicenter studies to meet these needs. Improving the infrastructure that can support these efforts will be instrumental in future success.

Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy

“…It will therefore enable us to determine and confirm efficacy of novel therapeutics across multiple models and pathologies. The advantage of using such chronic models of epilepsies and associated comorbidities, as well as comparing them to milder forms of the same syndromes, will allow us to investigate in more detail the full spectrum of efficacy and tolerability of novel therapeutics against a large range of clinically relevant end points and outcomes …”

Inflammation in Epileptic Encephalopathies

“…Animal models of eary life epilepsies and epileptic encephalopathies have started to generate an increasing amount of evidence for new therapy targets, candidate therapy targets and putative mechanisms incolved in epileptogenesis and comorbidogenesis of these early life epilepsies. Already few of these candidate drugs tested in animal models have entered clinical trials with promising results, lending value to the hope that the horizon of new pediatric therapy discovery will change to include not only extrapolation trials, but also novel pediatric preclinical therapy discovery using age-specific animal models of epileptic encephalopathies (Galanopoulou & Mowrey 2016). …”

A universal automated tool for reliable detection of seizures in rodent models of acquired and genetic epilepsy

“…However, the focus of translational research and drug development for the epilepsies has now shifted from the development of more antiseizure drugs to the development of antiepileptogenic and disease‐modifying therapies. Prolonged electroencephalographic ( EEG ) recordings in chronic epilepsy models are a critical part of the drug development testing paradigm for these therapies . For this, an efficient and accurate measure of quantitating the occurrence of spontaneous seizures is critical …”

“…Studies utilizing EEG typically involve comparison of measurements obtained from different experimental groups or from the same experimental group at different times. Given the heterogeneity of epilepsy and, in some cases, the low frequency of spontaneously occurring seizures, to appropriately power antiepileptogenesis and disease modification studies, it is mandatory to have a large number of animals per cohort as well as multiple and prolonged periods of recording to establish whether the experimental treatments are successful in preventing or modifying the progression of epilepsy …”